ORBIMED ADVISORS LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001055951
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2024 · 113 positions · Total reported value $5.22B · Top-10 concentration 43.9% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 60.6% · 34 new · 29 cut · 23 exited
Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking
In its Q3 2024 13F filing, ORBIMED ADVISORS LLC disclosed 113 equity positions with a combined reported value of $5.22B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 43.9% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2024 were EWTX ($400.93M), SVA ($340.00M), LLY ($299.09M). By sector, the heaviest allocations are Health Care 84.0%, Industrials 1.0%. Versus the prior quarter, allocation shifted toward Health Care (+4.2pp) and away from Consumer Discretionary (-0.9pp), Other (-2.8pp).
Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions. The portfolio's overlap with the prior quarter was 73% of names.
The largest new positions opened in Q3 2024 were MBX ($99.04M), UHS ($35.73M), BIOA ($29.61M).
Of the 23 positions fully exited versus the prior quarter, the largest were VRNA ($41.38M), DXCM ($32.87M), HRTX ($22.80M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2024)
- MBX MBX BIOSCIENCES INC COM · $99.04M
- UHS UNIVERSAL HLTH SVCS INC · $35.73M
- BIOA BIOAGE LABS INC COM · $29.61M
- PHAT PHATHOM PHARMACEUTICALS INC · $26.20M
- CGON CG ONCOLOGY INC COM · $26.08M
- CRBP CORBUS PHARMACEUTICALS HLDGS COM NEW · $18.83M
- MEDP MEDPACE HLDGS INC · $14.99M
- GILD GILEAD SCIENCES INC · $12.72M
Fully Exited (vs previous quarter)
- VRNA VERONA PHARMA PLC · prev qtr: $41.38M
- DXCM DEXCOM INC · prev qtr: $32.87M
- HRTX HERON THERAPEUTICS INC · prev qtr: $22.80M
- MORF MORPHIC HLDG INC · prev qtr: $20.87M
- ALXO ALX ONCOLOGY HLDGS INC · prev qtr: $11.42M
- PGNY PROGYNY INC COM · prev qtr: $7.44M
- PFE PFIZER INC · prev qtr: $7.00M
- CATX PERSPECTIVE THERAPEUTICS INC · prev qtr: $4.91M
Insider Transactions (Form 4)
Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-10 | Buy | Electra Therapeutics, Inc. | 2,000 | $8.45 | SEC filing |
| 2026-11-10 | Buy | Electra Therapeutics, Inc. | 20,700 | $8.45 | SEC filing |
| 2026-11-09 | Buy | Electra Therapeutics, Inc. | 16,000 | $8.24 | SEC filing |
| 2026-11-09 | Buy | Electra Therapeutics, Inc. | 4,000 | $8.24 | SEC filing |
| 2026-11-06 | Buy | Electra Therapeutics, Inc. | 39,600 | $7.85 | SEC filing |
| 2026-11-06 | Buy | Electra Therapeutics, Inc. | 9,816 | $7.85 | SEC filing |
| 2026-11-05 | Buy | Electra Therapeutics, Inc. | 125,200 | $7.31 | SEC filing |
| 2026-11-05 | Buy | Electra Therapeutics, Inc. | 30,891 | $7.31 | SEC filing |
Fund Profile
ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.
Investment Approach
ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.
Asset Classes
ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.
Key People
Samuel Isen - Co-founder and Managing Partner
Steven Bloom - Co-founder and Managing Partner
The firm also has several other managing partners and investment professionals
Notable Facts
ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.
This information is based on public disclosures; investment decisions should reference official filings.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
15.02M | $400.93M | 7.68% | Hold | |
| 2 |
|
2.72M | $340.00M | 6.52% | Hold | |
| 3 |
|
337.60K | $299.09M | 5.73% | Hold | |
| 4 |
|
3.27M | $274.28M | 5.26% | Hold | |
| 5 |
|
433.80K | $213.11M | 4.08% | Reduce | |
| 6 |
|
7.96M | $203.29M | 3.90% | Hold | |
| 7 |
|
813.00K | $157.59M | 3.02% | Reduce | |
| 8 |
|
1.32M | $149.44M | 2.86% | Hold | |
| 9 |
|
782.00K | $129.97M | 2.49% | Reduce | |
| 10 |
|
344.40K | $124.42M | 2.38% | Add | |
| 11 |
|
8.29M | $120.18M | 2.30% | Reduce | |
| 12 |
|
204.50K | $110.86M | 2.12% | Reduce | |
| 13 |
|
179.00K | $104.66M | 2.01% | Add | |
| 14 |
|
2.25M | $100.53M | 1.93% | Hold | |
| 15 |
|
3.81M | $99.04M | 1.90% | New | |
| 16 |
|
2.32M | $93.12M | 1.78% | Reduce | |
| 17 |
|
1.79M | $87.74M | 1.68% | Hold | |
| 18 |
|
687.50K | $87.28M | 1.67% | Hold | |
| 19 |
|
252.30K | $81.29M | 1.56% | Add | |
| 20 |
|
5.78M | $78.31M | 1.50% | Hold | |
| 21 |
|
575.00K | $74.75M | 1.43% | Add | |
| 22 |
|
3.03M | $71.14M | 1.36% | Hold | |
| 23 |
|
151.00K | $70.23M | 1.35% | Hold | |
| 24 |
|
250.30K | $68.84M | 1.32% | Hold | |
| 25 |
|
7.56M | $63.08M | 1.21% | Reduce | |
| 26 |
|
1.02M | $59.16M | 1.13% | Reduce | |
| 27 |
|
1.26M | $57.18M | 1.10% | Reduce | |
| 28 |
|
106.20K | $55.22M | 1.06% | Reduce | |
| 29 |
|
1.05M | $53.66M | 1.03% | Reduce | |
| 30 |
|
84.40K | $52.21M | 1.00% | Reduce | |
| 31 |
|
73.11M | $49.43M | 0.95% | Hold | |
| 32 |
|
45.20K | $47.52M | 0.91% | Add | |
| 33 |
|
679.82K | $46.31M | 0.89% | Add | |
| 34 |
|
1.39M | $44.56M | 0.85% | Reduce | |
| 35 |
|
387.00K | $44.22M | 0.85% | Reduce | |
| 36 |
|
22.36M | $41.15M | 0.79% | Hold | |
| 37 |
|
766.91K | $40.49M | 0.78% | Reduce | |
| 38 |
|
1.93M | $37.06M | 0.71% | Hold | |
| 39 |
|
6.94M | $36.66M | 0.70% | Hold | |
| 40 |
|
1.27M | $36.64M | 0.70% | Reduce | |
| 41 |
|
911.42K | $35.88M | 0.69% | Add | |
| 42 |
|
156.00K | $35.73M | 0.69% | New | |
| 43 |
|
123.90K | $35.60M | 0.68% | Reduce | |
| 44 |
|
302.22K | $34.82M | 0.67% | Reduce | |
| 45 |
|
675.87K | $29.87M | 0.57% | Hold | |
| 46 |
|
1.42M | $29.61M | 0.57% | New | |
| 47 |
|
6.06M | $27.63M | 0.53% | Add | |
| 48 |
|
3.57M | $26.76M | 0.51% | Add | |
| 49 |
|
1.45M | $26.20M | 0.50% | New | |
| 50 |
|
691.11K | $26.08M | 0.50% | New | |
FAQ
What did ORBIMED ADVISORS LLC buy in 2024-Q3?
In its 2024-Q3 13F filing, ORBIMED ADVISORS LLC reported 113 equity positions worth $5.22B in aggregate; its largest disclosed positions were EWTX ($400.93M), SVA ($340.00M), LLY ($299.09M).
How large is ORBIMED ADVISORS LLC's portfolio?
ORBIMED ADVISORS LLC reported $5.22B of long equity holdings across 113 positions as of 2024-Q3. Top-10 holdings account for 43.9% of reported value.
What is ORBIMED ADVISORS LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.